Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 9/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | GHSR | Q92847 | 1/20 | 0.73 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.61 |
| ▸ | NAAA | Q02083 | 1/20 | 0.61 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10599308 | 1.00 | EPHX1 (1.00) | EPHX1ALDH1A1HTTGHSRHDAC1 | |
| SCHEMBL422504 | 1.00 | EPHX1 (1.00) | EPHX1ALDH1A1HTTGHSRHDAC1 | |
| SCHEMBL5020899 | 1.00 | EPHX1 (1.00) | EPHX1ALDH1A1HTTGHSRHDAC1 | |
| SCHEMBL4138192 | 1.00 | EPHX1 (1.00) | EPHX1ALDH1A1HTTGHSRHDAC1 | |
| SCHEMBL4603476 | 1.00 | EPHX1 (1.00) | EPHX1ALDH1A1HTTGHSRHDAC1 | |
| SCHEMBL11671083 | 1.00 | EPHX1 (1.00) | EPHX1ALDH1A1HTTGHSRHDAC1 | |
| SCHEMBL17119069 | 1.00 | EPHX1 (1.00) | EPHX1ALDH1A1HTTGHSRHDAC1 | |
| SCHEMBL7722626 | 0.98 | EPHX1 (0.97) | EPHX1ALDH1A1HTTGHSRHDAC1 | |
| Dimethylamine SCHEMBL9100861 | 0.97 | EPHX1 (0.94) | EPHX1ALDH1A1HTTGHSRHDAC1 | |
| SCHEMBL4604785 | 0.93 | EPHX1 (0.87) | EPHX1ALDH1A1HTTGHSRHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6320862-A | — | — | None | — | — | JP | disclosed |
| US-10030138-B2 | High thermal conductivity thermoplastic resin composition with excellent injection moldability | KANEKA CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-20160152823-A1 | HIGH THERMAL CONDUCTIVITY THERMOPLASTIC RESIN COMPOSITION WITH EXCELLENT INJECTION MOLDABILITY | KANEKA CORPORATION (JP) | 2016-06-02 | — | — | US | disclosed |
| CN-103664704-B | A kind of synthetic N, the method for N '-disubstituted urea | NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2016-05-18 | — | — | CN | disclosed |
| EP-3018172-A1 | HIGH THERMAL CONDUCTIVITY THERMOPLASTIC RESIN COMPOSITION WITH EXCELLENT INJECTION MOLDABILITY | Kaneka Corporation (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-1881036-B1 | BIODEGRADABLE RESIN COMPOSITION AND MOLDED ARTICLE PRODUCED FROM THE SAME | KANEKA CORP (JP) | 2015-04-15 | — | — | EP | disclosed |
| US-8815951-B2 | Inhibitors of epoxide hydrolases for the treatment of inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815951-B2 | Inhibitors of epoxide hydrolases for the treatment of inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-26 | — | — | US | disclosed |
| CN-103664704-A | Method for synthesizing N,N'-disubstituent urea | UNIV NANJING SCIENCE & TECH | 2014-03-26 | — | — | CN | disclosed |
| US-20130202882-A1 | HIGHLY THERMALLY CONDUCTIVE RESIN MOLDED ARTICLE, AND MANUFACTURING METHOD FOR SAME | KANEKA CORPORATION (JP) | 2013-08-08 | — | — | US | disclosed |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | disclosed |
| US-6506901-B2 | 1-(9H-Carbazol-4-yloxy)-3-((1-(7-trifluoromethyl-quinolin-4-yl) -piperidin-4-lmethyl)-amino)-propan-2-ol, for example; treating diabetes, urinary continence, atherosclerosis, gastrointestinal disorders, glaucoma | WYETH | 2003-01-14 | — | — | US | disclosed |
| US-6451814-B1 | SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION | WYETH | 2002-09-17 | — | — | US | disclosed |
| US-6416922-B2 | DRY PROCESSING PHOTOGRAPHY | FUJI PHOTO FILM CO., LTD. (JP) | 2002-07-09 | — | — | US | disclosed |
| US-20020037907-A1 | Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-28 | — | — | US | disclosed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | disclosed |
| WO-2002006255-A2 | HYDROXY-(PIPERIDIN-4-YL-METHYLAMINO)-ALKYL BETA-3 ADRENERGIC RECEPTOR ANTAGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| US-20010019806-A1 | Azomethine dye precursor, image-forming material, and image-forming method | FUJIFILM CORPORATION (JP) | 2001-09-06 | — | — | US | disclosed |
| JP-H06320862-A | REVERSIBLE THERMAL RECORDING MATERIAL | MITSUBISHI PAPER MILLS LTD | 1994-11-22 | — | — | JP | disclosed |
| US-4444863-A | UREA COMPOUND | FUJI PHOTO FILM CO., LTD. (JP) | 1984-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | EPHX1 1421/4885ALDH1A1 725/4885HTT 1613/4885 |
| US-20020037907-A1 | Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists | GPR119, ADRB1, ADRB2 | EPHX1 975/4885ALDH1A1 783/4885HTT 715/4885 |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | EPHX1 1600/4885ALDH1A1 524/4885HTT 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.